COMMUNIQUÉS West-GlobeNewswire

Rapport Therapeutics to Participate in Upcoming Investor Conferences
24/02/2026
BOSTON and SAN DIEGO, Feb. 24, 2026 (GLOBE NEWSWIRE) -- Rapport Therapeutics, Inc. (Nasdaq: RAPP) (“Rapport” or the “Company”), a clinical-stage biotechnology company dedicated to the discovery and development of small [...]
Spyre Therapeutics to Participate in Upcoming March Investor Conferences
24/02/2026
WALTHAM, Mass., Feb. 24, 2026 (GLOBE NEWSWIRE) -- Spyre Therapeutics, Inc. (NASDAQ: SYRE), a clinical-stage biotechnology company pioneering long-acting antibodies and antibody combinations to redefine the standard of [...]
Palvella Therapeutics Announces Proposed Public Offering
24/02/2026
WAYNE, Pa., Feb. 24, 2026 (GLOBE NEWSWIRE) -- Palvella Therapeutics, Inc. (“Palvella”) (Nasdaq: PVLA), a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapies to treat [...]
Serina Therapeutics Announces Dosing of First Patient in Phase 1b Registrational Trial of SER-252 for Advanced Parkinson’s Disease
24/02/2026
- Blinded evaluation of safety and tolerability data by the Safety Monitoring Committee from Cohort 1 and advancement to Cohort 2 is expected in 3Q 2026 – - Advancement reflects continued execution of capital-efficient [...]
Vaxcyte Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update
24/02/2026
Comprehensive VAX-31 Adult Phase 3 Clinical Program, Finalized in Consultation and Alignment with FDA, Advances with Three Phase 3 Studies Underway to Support Planned BLA Submission Topline Safety, Tolerability and [...]
UroGen Pharma to Present at the TD Cowen 46th Annual Health Care Conference
24/02/2026
PRINCETON, N.J., Feb. 24, 2026 (GLOBE NEWSWIRE) -- UroGen Pharma Ltd. (Nasdaq: URGN), a biotech company dedicated to developing and commercializing innovative solutions that treat urothelial and specialty cancers, today [...]
Day One Reports Fourth Quarter and Full Year 2025 Financial Results and Reaffirms 2026 Outlook and Revenue Guidance
24/02/2026
OJEMDA™ 2025 momentum reflected by Q4 and full year net product revenues of $52.8 million and $155.4 million, respectively 2026 U.S. net product revenue projected at $225 - $250 million Expanded pipeline with January [...]
Cytokinetics Reports Fourth Quarter 2025 Financial Results and Provides Business Update
24/02/2026
MYQORZO® Approved for Adults with Symptomatic Obstructive HCM in U.S., China and Europe; U.S. Launch Underway with First Prescriptions Dispensed within Days of Drug Availability Supplemental NDA for MAPLE-HCM Submitted [...]
Aktis Oncology to Present at Upcoming March Investor Conferences
24/02/2026
BOSTON, Feb. 24, 2026 (GLOBE NEWSWIRE) -- Aktis Oncology, Inc. (NASDAQ:AKTS), a clinical-stage oncology company focused on expanding the breakthrough potential of targeted radiopharmaceuticals to large patient [...]
BridgeBio Reports Fourth Quarter and Full Year 2025 Financial Results and Commercial Updates
24/02/2026
$154.2 million in total fourth quarter revenues, net, and $502.1 million in full year revenues, net, primarily comprised of net product revenue of $146.0 million and $362.4 million, respectively BridgeBio reported three [...]
Cardiff Oncology Reports Full Year 2025 Results and Provides Business Update
24/02/2026
Reported positive update from Phase 2 CRDF-004 trial in first-line RAS-mutated mCRC, with the 30 mg onvansertib + FOLFIRI/bev arm demonstrating: • Robust ORR of 72.2% (vs 43.2% with combined SoC of FOLFOX/bev and [...]
Supernus Announces Record Fourth Quarter and Full Year 2025 Financial Results
24/02/2026
Record total revenues of $211.6 million and $719.0 million in the fourth quarter and full year 2025, a 21% and 9% increase compared to same periods last year. Combined revenues of the Company's four growth products [...]
Rapid Micro Biosystems to Announce Fourth Quarter and Full Year 2025 Financial Results on March 12, 2026
24/02/2026
LEXINGTON, Mass., Feb. 24, 2026 (GLOBE NEWSWIRE) -- Rapid Micro Biosystems, Inc. (Nasdaq: RPID) (the “Company”), an innovative life sciences technology company providing mission-critical automation solutions to [...]
Globus Medical Reports Fourth Quarter and Full Year 2025 Results
24/02/2026
AUDUBON, Pa., Feb. 24, 2026 (GLOBE NEWSWIRE) -- Globus Medical, Inc. (NYSE: GMED), a leading musculoskeletal technology solutions company, today announced its financial results for the fourth quarter and year ended [...]
Dentsply Sirona Appoints James Forbes and Brian McKeon to Board of Directors
24/02/2026
New directors bring decades of financial leadership and board experience to enhance strategic oversight of Return-to-Growth action plan and long-term value creation CHARLOTTE, N.C., Feb. 24, 2026 (GLOBE NEWSWIRE) -- [...]
Merit Medical Reports Fourth Quarter and Full Year 2025 Results and Issues Fiscal Year 2026 Guidance
24/02/2026
Fourth Quarter Highlights† Reported revenue of $393.9 million, up 11% Constant currency revenue* and constant currency revenue, organic* up 10% and up 7%, respectively GAAP operating margin of 13.8%, compared to 10.3% [...]
Revolution Medicines to Participate in TD Cowen 46th Annual Health Care Conference
24/02/2026
REDWOOD CITY, Calif., Feb. 24, 2026 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a late-stage clinical oncology company developing targeted therapies for patients with RAS-addicted cancers, today [...]
Ceribell Reports Fourth Quarter and Full Year 2025 Financial Results
24/02/2026
SUNNYVALE, Calif., Feb. 24, 2026 (GLOBE NEWSWIRE) -- CeriBell, Inc. (Nasdaq: CBLL) (“Ceribell”), a medical technology company focused on transforming the diagnosis and management of patients with serious neurological [...]
Amwell® to Participate in Upcoming Investor Conference
24/02/2026
BOSTON, Feb. 24, 2026 (GLOBE NEWSWIRE) -- Amwell ® (NYSE: AMWL), a leading provider of a comprehensive SaaS-based software platform for technology-enabled healthcare, today announced that Mark Hirschhorn, CFO and COO, [...]

Pages